Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chang S Chan

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Integrated metabolic and genetic analysis reveals distinct features of primary differentiated thyroid cancer and its metastatic potential in humansEduardo Cararo-Lopes, Akshada Sawant, Dirk Moore, et al.
The Oncologist|August 28, 2016
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory CancersKim M Hirshfield, Denis Tolkunov, Hua Zhong, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Nature|September 1, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Integrated metabolic and genetic analysis reveals distinct features of primary differentiated thyroid cancer and its metastatic potential in humansEduardo Cararo-Lopes, Akshada Sawant, Dirk Moore, et al.
The Oncologist|August 28, 2016
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory CancersKim M Hirshfield, Denis Tolkunov, Hua Zhong, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Nature|September 1, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Pageof 4